Diabetic Retinopathy Market , 2012-2023

January 2018 | 220 pages | ID: D5FFDD411AFEN
Precision Business Insights (PBI)

Abstracts

Report Snapshot of Diabetic Retinopathy Market: Diabetic retinopathy is the most common form of diabetic eye disease. Diabetic retinopathy usually affects the people with diabetes from number of years. High glucose levels in the cause damage to the retinal blood vessels is the main manifestation in diabetic retinopathy. In some other cases, the retinal blood vessels will be swollen (macular oedema) with a fluid leaking into rear of eye. In few cases, on the surface of the retinal blood vessels will grow abnormally. If diabetic retinopathy is not properly treated, can progressively become more serious and seriously affects vision which may leads to blindness.

Global Market Outline: Diabetic Retinopathy Market

Diabetic Retinopathy will affect both type 1 and type 2 diabetic patients and due to the abundant increase in the pool of patients with Diabetes, According to the World Health Organisation (WHO), 41 % of global population with diabetes are geriatric patients which is highly attributing the growth of the diabetic retinopathy market. Furthermore, rise in healthcare infrastructure up-gradation, rise in demand for the early diagnosis devices are the few factors having significant impact in driving the diabetic retinopathy market. However, paucity of skilled ophthalmologist, lack of primary infrastructure and insurance facilities are some of the restraining factors that are hampering the growth of diabetic retinopathy market.

The global diabetic retinopathy treatment market is segmented on the basis of treatment, end users, type, and geographical regions.

Based on the type, global diabetic retinopathy treatment market is segmented as:

• Proliferative Diabetic Retinopathy
• Diabetic Macular Edema

Based on the drug class, the global diabetic retinopathy treatment market is segmented as:

• Corticosteroids
• Anti-VEGF (vascular endothelial growth factor)

Based on the basis distribution channels, the global Diabetic retinopathy Treatment Market is segmented as:

• Ophthalmic Clinics
• Hospital Pharmacies
• Retail pharmacies

Diabetic retinopathy can be treated by various methods depending on the stage of disease. Diabetic retinopathy is one of the major causes of blindness in adult population in America. As per, World Health Organisation (WHO), 347 Mn people were suffering from diabetes globally in 2012, in which 11% population are having diabetic retinopathy. Increase in focus on Asia-pacific and LAMEA regions by various vendors is expected to boost growth of the market According to the World Bank, in 2015,10.4% of rate of prevalence of diabetes was observed in Brazil. Strategic acquisitions, geographic expansion, agreements, partnerships and new product launches are the most vital strategic implementations by most of the companies in the market of diabetic retinopathy.

On the basis of regions, the global market of diabetic retinopathy has been segmented into five key regions, Latin America North America, Asia-Pacific, Europe, and Middle East & Africa. North America dominates the market followed by Asia-Pacific and Europe. The factors that are attributing for the market growth in North America are, people with high obesity rates are more prone to diabetes conditions. Large patient pool in European region with diabetic retinopathy is expected to drive the growth of the market. In emerging economies, due to the improvement in the healthcare infrastructure and rise in awareness in the people Owing to improved infrastructure and awareness among the people, improving on the quality of life (QALY) in diabetic patients, rise in demand of early detection and treatment of chronic conditions such as diabetic retinopathy are the factors that are driving the growth of the diabetic retinopathy market in Asia Pacific regions.

Some of the players in diabetic retinopathy market are Abbott Laboratories (U.S.), Alimera Sciences (U.S.), Allergan plc (Ireland.), Ampio Pharmaceuticals. (U.S.), Bayer AG (Germany), F. Hoffmann-La Roche (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Regeneron Pharmaceuticals Inc. (U.S.), and Valeant (Canada)

In 2017, Roche got FDA approval for Lucentis ( Ranibizumab injection) for the treatment of diabetic retinopathy

In 2014, Regeneron Pharmaceuticals, EYLEA® (aflibercept) injection received USFDA breakthrough therapy designation for to treat diabetic retinopathy in patients with diabetic macular edema (DME)

In 2014, Regeneron Pharmaceuticals, EYLEA® (aflibercept) injection received European Commission to treat diabetic retinopathy in patients with diabetic macular edema (DME)

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL DIABETIC RETINOPATHY MARKET INTRODUCTION

2.1. Global Diabetic Retinopathy Market – Taxonomy
2.2. Global Diabetic Retinopathy Market –Definitions
  2.2.1. Diabetic Retinopathy Type
  2.2.2. Distribution Channel

3. GLOBAL DIABETIC RETINOPATHY MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Diabetic Retinopathy Market Dynamic Factors - Impact Analysis

4. GLOBAL DIABETIC RETINOPATHY MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis

5. GLOBAL DIABETIC RETINOPATHY MARKET, BY DIABETIC RETINOPATHY TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

5.1. Proliferative Diabetic Retinopathy
  5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Diabetic Macular Edema
  5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis

6. GLOBAL DIABETIC RETINOPATHY MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

6.1. Corticosteroids
  6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Anti-VEGF (Vascular Endothelial Growth Factor)
  6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis

7. GLOBAL DIABETIC RETINOPATHY MARKET, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

7.1. Ophthalmic Clinics
  7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Hospital Pharmacies
  7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Retail Pharmacies
  7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis
7.4. Online Pharmacies
  7.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.4.3. Market Opportunity Analysis

8. GLOBAL DIABETIC RETINOPATHY MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

8.1. North America
  8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Diabetic Retinopathy Market - Opportunity Analysis Index, By Diabetic Retinopathy Type, By Drug Class, By Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA DIABETIC RETINOPATHY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

9.1. Diabetic Retinopathy Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.1.1. Proliferative Diabetic Retinopathy
  9.1.2. Diabetic Macular Edema
9.2. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.2.1. Corticosteroids
  9.2.2. Anti-VEGF (Vascular Endothelial Growth Factor)
9.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.3.1. Ophthalmic Clinics
  9.3.2. Hospital Pharmacies
  9.3.3. Retail pharmacies
  9.3.4. Online Pharmacies
9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  9.4.1. U.S.
  9.4.2. Canada
9.5. North America Diabetic Retinopathy Market - Opportunity Analysis Index, By Diabetic Retinopathy Type, By Drug Class, By Distribution Channel, and Country, 2017 – 2023
9.6. North America Diabetic Retinopathy Market Dynamics – Trends

10. EUROPE DIABETIC RETINOPATHY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

10.1. Diabetic Retinopathy Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Proliferative Diabetic Retinopathy
  10.1.2. Diabetic Macular Edema
10.2. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.2.1. Corticosteroids
  10.2.2. Anti-VEGF (Vascular Endothelial Growth Factor)
10.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.3.1. Ophthalmic Clinics
  10.3.2. Hospital Pharmacies
  10.3.3. Retail pharmacies
  10.3.4. Online Pharmacies
10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  10.4.1. Germany
  10.4.2. UK
  10.4.3. France
  10.4.4. Spain
  10.4.5. Italy
  10.4.6. Russia
  10.4.7. Poland
  10.4.8. Rest of Europe
10.5. Europe Diabetic Retinopathy Market - Opportunity Analysis Index, By Diabetic Retinopathy Type, By Drug Class, By Distribution Channel, and Country, 2017 – 2023
10.6. Europe Diabetic Retinopathy Market Dynamics – Trends

11. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

11.1. Diabetic Retinopathy Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Proliferative Diabetic Retinopathy
  11.1.2. Diabetic Macular Edema
11.2. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.2.1. Corticosteroids
  11.2.2. Anti-VEGF (Vascular Endothelial Growth Factor)
11.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.3.1. Ophthalmic Clinics
  11.3.2. Hospital Pharmacies
  11.3.3. Retail pharmacies
  11.3.4. Online Pharmacies
11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  11.4.1. Japan
  11.4.2. China
  11.4.3. India
  11.4.4. ASEAN
  11.4.5. Australia & New Zealand
  11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Diabetic Retinopathy Market - Opportunity Analysis Index, By Diabetic Retinopathy Type, By Drug Class, By Distribution Channel, and Country, 2017 – 2023
11.6. Asia-Pacific Diabetic Retinopathy Market Dynamics – Trends

12. LATIN AMERICA DIABETIC RETINOPATHY MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

12.1. Diabetic Retinopathy Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Proliferative Diabetic Retinopathy
  12.1.2. Diabetic Macular Edema
12.2. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.2.1. Corticosteroids
  12.2.2. Anti-VEGF (Vascular Endothelial Growth Factor)
12.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.3.1. Ophthalmic Clinics
  12.3.2. Hospital Pharmacies
  12.3.3. Retail pharmacies
  12.3.4. Online Pharmacies
12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  12.4.1. Brazil
  12.4.2. Mexico
  12.4.3. Argentina
  12.4.4. Venezuela
  12.4.5. Rest of Latin America
12.5. Latin America Diabetic Retinopathy Market - Opportunity Analysis Index, By Diabetic Retinopathy Type, By Drug Class, By Distribution Channel, and Country, 2017 – 2023
12.6. Latin America Diabetic Retinopathy Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA DIABETIC RETINOPATHY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

13.1. Diabetic Retinopathy Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.1.1. Proliferative Diabetic Retinopathy
  13.1.2. Diabetic Macular Edema
13.2. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.2.1. Corticosteroids
  13.2.2. Anti-VEGF (Vascular Endothelial Growth Factor)
13.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.3.1. Ophthalmic Clinics
  13.3.2. Hospital Pharmacies
  13.3.3. Retail pharmacies
  13.3.4. Online Pharmacies
13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  13.4.1. Gulf Cooperation Council (GCC) Countries
  13.4.2. Israel
  13.4.3. South Africa
  13.4.4. Rest of MEA
13.5. MEA Diabetic Retinopathy Market - Opportunity Analysis Index, By Diabetic Retinopathy Type, By Drug Class, By Distribution Channel, and Country, 2017 – 2023
13.6. MEA Diabetic Retinopathy Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. Abbott Laboratories (U.S.)
  14.2.2. Alimera Sciences (U.S.)
  14.2.3. Allergan plc (Ireland.)
  14.2.4. Ampio Pharmaceuticals. (U.S.)
  14.2.5. Bayer AG (Germany)
  14.2.6. F. Hoffmann-La Roche (Switzerland)
  14.2.7. Novartis AG (Switzerland)
  14.2.8. Pfizer Inc. (U.S.)
  14.2.9. Regeneron Pharmaceuticals Inc. (U.S.)
  14.2.10. Valeant (Canada)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS